Read on
Industrial biotech company Biosyntia from Copenhagen, Denmark, has closed its Series B investment round of a size of 11.5mEUR. Using cutting-edge biotechnology and proprietary R&D tools and insights, Biosynthia is developing precision fermentation processes to replace fossil-based production methods for active compounds with bio-based ones.
Editorial office / Copenhagen

The 11.5 million euros financing round was secured through the investment of the European Circular Bioeconomy Fund (ECBF), acting as a lead investor, and two existing investors, Sofinnova Partners and Novo Seeds, the early-stage investment and company creation team of Novo Holdings A/S .

Nutritional ingredients

The ECBF Fund invests in companies developing innovative technologies, circular business models and sustainable bio-based products. This includes the industrial biotech company Biosyntia, which produces nutritional active ingredients in a sustainable manner. The production of some of these nutritional ingredients, such as biotin, was previously possible only with the use of petrochemical processes. Using biotechnology as well as proprietary methods and IP, the company is developing unique precision fermentation processes to replace fossil resources and toxic chemicals from production.

Biosyntia intends to use the Series B investment to both expand its product range and start the production phase of its sustainably produced nutritional ingredients. The first product to be marketed is a bio-based biotin (vitamin B7) that can be used in food supplements, food and beauty products.

Image: Bits And Splits/Shutterstock